Research programme: antibody drug conjugates - Medilink Therapeutics
Alternative Names: Project 3; Project 5; Project 6Latest Information Update: 20 Jun 2022
At a glance
- Originator MediLink Therapeutics
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 20 Jun 2022 Preclinical trials in Solid tumours in China (Parenteral), prior to June 2022 (Medilink Therapeutics pipeline, June 2022)
- 14 Mar 2022 Research programme: antibody drug conjugates is available for licensing as of 14 Mar 2022
- 14 Mar 2022 Medilink Therapeutics has patent protection for antibody drug conjugates linker payload technologies